MACROGENICS, INC. (MGNX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 59.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $59.95M | (m) |
| 2026-03-31 | (m) | $4.19M | (m) |
| 2025-12-31 | (m) | $-74.62M | (m) |
| 2025-09-30 | (m) | $-75.89M | (m) |
| 2025-06-30 | (m) | $-36.40M | (m) |
| 2025-03-31 | (m) | $-55.81M | (m) |
| 2024-12-31 | (m) | $-66.97M | (m) |
| 2024-09-30 | (m) | $-97.62M | (m) |
| 2024-06-30 | (m) | $-136.37M | (m) |
| 2024-03-31 | (m) | $-23.24M | (m) |
| 2023-12-31 | (m) | $-9.06M | (m) |
| 2023-09-30 | (m) | $49.82M | (m) |
| 2023-06-30 | (m) | $7.45M | (m) |
| 2023-03-31 | (m) | $-91.32M | (m) |
| 2022-12-31 | (m) | $-119.76M | (m) |
| 2022-09-30 | (m) | $-190.58M | (m) |
| 2022-06-30 | (m) | $-218.66M | (m) |
| 2022-03-31 | (m) | $-217.29M | (m) |
| 2021-12-31 | (m) | $-202.12M | (m) |
| 2021-09-30 | (m) | $-146.18M | (m) |
| 2021-06-30 | (m) | $-129.34M | (m) |
| 2021-03-31 | (m) | $-136.29M | (m) |
| 2020-12-31 | (m) | $-129.74M | (m) |
| 2020-09-30 | (m) | $-158.05M | (m) |
| 2020-06-30 | (m) | $-166.64M | (m) |
| 2020-03-31 | (m) | $-151.52M | (m) |
| 2019-12-31 | (m) | $-151.81M | (m) |
| 2019-09-30 | (m) | $-166.06M | (m) |
| 2019-06-30 | (m) | $-155.46M | (m) |
| 2019-03-31 | (m) | $-166.93M | (m) |
| 2018-12-31 | (m) | $-171.45M | (m) |
| 2018-09-30 | (m) | $-21.08M | (m) |
| 2018-06-30 | (m) | $-34.10M | (m) |
| 2018-03-31 | (m) | $-31.51M | (m) |
| 2017-12-31 | (m) | $-19.63M | (m) |
| 2017-09-30 | (m) | $-160.14M | (m) |
| 2017-06-30 | (m) | $-146.94M | (m) |
| 2017-03-31 | (m) | $-65.82M | (m) |
| 2016-12-31 | (m) | $-58.53M | (m) |
| 2016-09-30 | (m) | $-52.20M | (m) |
| 2016-06-30 | (m) | $-33.79M | (m) |
| 2016-03-31 | (m) | $-95.63M | (m) |
| 2015-12-31 | (m) | $-20.14M | (m) |
| 2015-09-30 | (m) | $-10.71M | (m) |
| 2015-06-30 | (m) | $807.00K | (m) |
| 2015-03-31 | (m) | $9.92M | (m) |
| 2014-12-31 | (m) | $-38.31M | (m) |
| 2014-09-30 | (m) | $-22.50M | (m) |
| 2014-06-30 | (m) | $-11.97M | (m) |
| 2014-03-31 | (m) | $-3.27K | (m) |
| 2013-12-31 | (m) | $-260.83K | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | $-3.16M | (m) |
| 2013-03-31 | (m) | $675.75K | (m) |
| 2012-12-31 | (m) | $8.36M | (m) |
| 2012-09-30 | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) |
| 2011-12-31 | (m) | $6.72M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |